|
Allergy Therapeutics PLC on Thursday said it is preparing to evaluate a dual primary listing on the Main Board of The Stock Exchange of Hong Kong Ltd. The Sussex, England-based biotechnology company is currently listed on the London Stock Exchange’s AIM. Allergy Therapeutics said a potential listing in Hong Kong, alongside its listing on AIM, reflected its desire to expand its presence in Asia and ‘become a global leader in allergy treatments’. The company said a HKEX listing and an associated equity offering ‘would broaden the company’s investor base to include Hong Kong and mainland Chinese investors, aligning with the company’s growth ambitions in the region.’ It added that the dual listing would enhance trading liquidity in its ordinary shares. Allergy Therapeutics said it is carrying out preparatory work to explore the possible dual listing. If it decides to proceed, the company said it would target the listing to become effective during the first half of 2026. Allergy Therapeutics noted that an application for a HKEX listing would be subject to review and approval by the HKEX and the Securities and Futures Commission of Hong Kong. Chief Executive Manuel Llobet said: ‘We believe that a dual listing in Hong Kong could be an important step forwards for the company. This initiative aligns well with our Asia expansion strategy and our aim to become a truly global player in the allergy immunotherapy field. ‘By establishing a presence on HKEX, we would be able to engage more directly with Asian investors and support our growth in Asian markets, which we see as a key driver for Allergy Therapeutics’ future success.’ Shares in Allergy Therapeutics rose 2.4% to 8.50 pence on Thursday afternoon in London. Copyright 2025 Alliance News Ltd. All Rights Reserved.
|
